Table 1.
Synthesis of data about general features and eligibility criteria of study population treated with UAE
| # | References | Study design | Mean age | Number of patients | Number of FB | Inclusion criteria | Exclusion criteria | Mean volume of treated FB | FB shrinkage (%) | Follow up period (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Burn et al. [9] | PRO | 39 | 18 | 32 | Age 18–53, a | – | 340 cm3 | 59 | 6 |
| 2 | Roth et al. [10] | PRO | NM | 79 | NM | – | – | 244.5 cm3 | 40 | 3 |
| 3 | Klein et al. [11] | PRO | 46 | 35 | NM | a, b | – | 209 ml | 49 | 6 |
| 4 | Zupi et al. [12] | PRO | 40 | 26 | NM | j | i, m, t | 276.8 ± 241.2 ml | 55 ± 16.9 | 6 |
| 5 | Spies et al. [13] | PRO | 43 | 100 | NM | Age 30–55, a, j | d, f, k, n | 148.7 ± 153.9 cm3 | 50.06 | 3 |
| 6 | Harman et al. [14] | PRO | 44 | 20 | 28 | – | – | 123 cm3 | 44.6 | 6 months |
| 7 | Pisco et al. [15] | RETR | 41 | 234 | NM | j, l | n | 110.5 cm3 | 60.7 | 6 |
| 8 | Naguib et al. [16] | RETR | 48 | 28 | 84 | a, b, j | d, c, g (10 cm), n, o, p | 51.6 cm3 | 52.62 | 3 |
| 73.27 | 12 | |||||||||
| 9 | Stampfl et al. [17] | PRO | 42 | 121 | NM | Age > 30, b (2 years), j | c, d, i, g, n, o, p, p, u | 137.2 ± 245.1 ml | 52.4 | 3 |
| 78.3 | 6 | |||||||||
| 91.2 | 12 | |||||||||
| 10 | Bilhim et al. [18] | PRO | 39 | 160 | NM | a | – | 201.5 cm3 | 53.1 | 3 |
| 52.95 | 6 | |||||||||
| 11 | Redecha et al. [19] | PRO | NM | 98 | NM | Age > 18, j | h | NM | 68.18 | 24 |
| 12 | Song et al. [20] | PRO | 43 | 60 | NM | a, j | d, e, i, n, p | 224.69 ml | 54.05 | 3 |
| 13 | Yoon et al. [21] | RETR | 42 | 67 | NM | a | d, i, n | 143.5 ± 135.4 cm3 | 42 ± 23.1 | 3 |
| 14 | Ukybassova et al. [22] | PRO | 43 | 337 | NM | Age > 18, j, l | c, d, f, n, o, p, q, r, s | 51.53 ± 65.53 mm3 | 9.95 | 3 |
| 32.18 | 6 | |||||||||
| 51.7 | 12 |
NM, not mentioned; FB, fibroid; PRO, prospective case series; RETR, retrospective case series
a- fibroid related disease, b- no desire for further pregnancies; c- pedunculated fibroids with more than 50% attachment; d- pregnancy; e- contraindications to MRI and Gadolinium use; f- major medical disease; g- fibroid diameter > 15 cm, h- postmenopause; i- other pelvic diseases; j- premenopause; k-lactating; l- presence of only intramural fibroids, m- subserosal fibroid, n- pelvic inflammatory disease, o- abnormal coagulation status, p- malignancy, q- abnormal endometrial biopsy results, r- abnormal PAP test, s- severe anemia, t- irregular margins and with a sonographic pattern of diffuse fibrosis, u- allergy to contrast material